MedPath

Norethisterone

Generic Name
Norethisterone
Brand Names
Activella 1/0.5 28 Day, Activelle, Alyacen 1/35, Alyacen 7/7/7, Amabelz 0.5/0.1 28 Day, Aranelle 28, Aurovela, Aurovela Fe, Aygestin, Balziva 28 Day, Blisovi 21 Fe 1.5/30 28 Day Pack, Blisovi 21 Fe 1/20 28 Day Pack, Blisovi 24 Fe 1/20 28 Day, Brevicon, Briellyn 28 Day, Camila 28 Day, Charlotte 24 Fe Chewable 28 Day, Combipatch, Cyclafem 1/35 28 Day, Cyclafem 7/7/7 28 Day, Cyonanz 28 Day, Dasetta 1/35 28 Day, Dasetta 7/7/7 28 Day, Deblitane 28 Day, Emzahh 28 Day, Errin 28 Day, Estalis, Etyqa 0.5/0.1 28 Day, Femcon Fe 28 Day, Femhrt 0.5/2.5 28 Day, Finzala 24 Fe Chewable 28 Day, Fyavolv, Gemmily 28 Day, Hailey 1.5/30 21 Day, Hailey 24 Fe 28 Day, Hailey Fe 1.5/30 28 Day, Hailey Fe 1/20 28 Day, Heather 28 Day, Incassia, Jencycla 28 Day, Jinteli, Junel 1.5/30 21 Day, Junel 1/20 21 Day, Junel Fe 1.5/30 28 Day, Junel Fe 1/20 28 Day, Junel Fe 24 1/20 28 Day, Kaitlib Fe 28 Day, Larin 1.5/30, Larin 1/20, Larin 24 Fe 1/20, Larin Fe 1.5/30, Larin Fe 1/20, Layolis Fe 28, Leena 28 Day, Lo Loestrin Fe 28 Day, Loestrin 1.5/30 21 Day, Loestrin 24 Fe 28 Day, Loestrin Fe 1/20 28 Day, Lolo, Lomedia 24 Fe, Lopreeza 1/0.5 28 Day, Lupaneta Pack 1-month, Lyleq 28 Day, Lyza, Melodetta 24 Fe Chewable 28 Day, Merzee 28 Day, Mibelas 24 Fe Chewable 28 Day, Microgestin 1.5/30 21 Day, Microgestin 1/20 21 Day, Microgestin 24 Fe 28 Day, Microgestin Fe 1.5/30 28 Day, Microgestin Fe 1/20 28 Day, Mimvey, Minastrin 24 Fe Chewable 28 Day, Myfembree, Necon 0.5/35 28 Day, Necon 1/35 28 Day, Necon 7/7/7 28 Day, Nexesta Fe 28 Day, Nora-BE 28 Day, Norlutate, Norlyda 28 Day, Norlyroc 28 Day, Nortrel 1/35 21 Day, Nortrel 1/35 28 Day, Nortrel 7/7/7 28 Day, Nylia 1/35 28 Day, Nylia 7/7/7 28 Day, Oriahnn 28 Day Kit, Ortho Micronor, Ortho Micronor 28 Day, Ortho-novum 7/7/7 28 Day, Philith 28 Day, Pirmella 1/35 28 Day, Pirmella 7/7/7 28 Day, Rhuzdah 28 Day, Select, Sharobel 28 Day, Synphasic, Tarina 24 Fe 1/20 28 Day, Tarina Fe 1/20 28 Day, Taysofy 28 Day, Taytulla 28 Day, Tilia Fe, Tri-legest 28 Day, Tulana 28 Day, Vyfemla 28 Day, Wera 28 Day, Wymzya Fe 28 Day, Zenchent
Drug Type
Small Molecule
Chemical Formula
C20H26O2
CAS Number
68-22-4
Unique Ingredient Identifier
T18F433X4S
Background

Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with levonorgestrel and its derivatives, and is the active form of several other progestins including norethynodrel and lynestrenol. Norethisterone mimics the actions of endogenous progesterone, albeit with a greater potency, and is used on its own or in combination with estrogen derivatives in a variety of applications including contraception and hormone replacement therapy. First derived in 1951 in Mexico City, norethisterone was originally intended for use as a remedy for irregular menstruation and endometriosis, and was not marketed for use as an oral contraceptive until 1962.

Indication

Norethisterone is indicated as an oral contraceptive when given as monotherapy or in combination with an estrogen component, such as ethinylestradiol or estradiol. In combination with an estrogen component, oral norethisterone is also indicated as a hormone replacement therapy in the treatment of postmenopausal osteoporosis and moderate-to-severe vasomotor symptoms arising from menopause. When applied via transdermal patch, the combination of norethisterone and estradiol is indicated for the treatment of hypoestrogenism, vulvovaginal atrophy, and moderate-severe vasomotor symptoms.

Norethisterone, taken in combination with intramuscular leuprolide, is also indicated for the symptomatic treatment of endometriosis-related pain.

Associated Conditions
Endometriosis related pain, Heavy Menstrual Bleeding, Moderate to Severe Vasomotor Symptoms, Osteoporosis, Postmenopausal Osteoporosis, Severe Pain, Vulvo Vaginal Atrophy, Hypoestrogenism, Moderate, severe, Vasomotor Symptoms caused by Menopause
Associated Therapies
Contraception, Hormone Replacement Therapy, Oral Contraceptives

The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial

Phase 2
Completed
Conditions
Endometriosis
Interventions
First Posted Date
2007-05-17
Last Posted Date
2015-03-30
Lead Sponsor
Boston Children's Hospital
Target Recruit Count
53
Registration Number
NCT00474851
Locations
🇺🇸

Children's Hospital Boston, Boston, Massachusetts, United States

Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)

Phase 3
Conditions
Endometriosis
Dysmenorrhea
Dyspareunia
Interventions
First Posted Date
2007-04-10
Last Posted Date
2012-10-25
Lead Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Target Recruit Count
112
Registration Number
NCT00458458
Locations
🇺🇸

SUNY Downstate Medical Center, Brooklyn, New York, United States

Genistein and Endometrial Hyperplasia

Phase 2
Completed
Conditions
Endometrial Hyperplasia
Interventions
Dietary Supplement: Genivis
Other: placebo
First Posted Date
2007-03-29
Last Posted Date
2008-12-19
Lead Sponsor
University of Messina
Target Recruit Count
59
Registration Number
NCT00453960
Locations
🇮🇹

Menopause Centre, Department of Gynecology and Obstetrics, Policlinico Universitario "G.Martino", Messina, Italy

Study of Safety and Efficacy of an Oral Contraceptive

Phase 3
Completed
Conditions
Contraception
Interventions
First Posted Date
2006-10-24
Last Posted Date
2013-04-22
Lead Sponsor
Warner Chilcott
Target Recruit Count
1683
Registration Number
NCT00391807
Locations
🇺🇸

Warner Chilcott Investigational Site, Tacoma, Washington, United States

Study of Bleeding With Extended Administration of an Oral Contraceptive

Phase 2
Completed
Conditions
Contraception
First Posted Date
2006-06-20
Last Posted Date
2008-05-08
Lead Sponsor
Warner Chilcott
Target Recruit Count
207
Registration Number
NCT00338052
Locations
🇺🇸

Warner Chilcott Investigational Site, Seattle, Washington, United States

Bleed Free Treatment of Menopausal Symptoms With New Ultra Low Dose Hormonal Combinations

Phase 3
Completed
Conditions
Menopause
Menopausal Vasomotor Symptoms
Interventions
First Posted Date
2005-09-16
Last Posted Date
2017-02-23
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
576
Registration Number
NCT00184795
Locations
🇬🇧

Novo Nordisk Investigational Site, WAtford, United Kingdom

Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer

Phase 3
Completed
Conditions
Breast Cancer
Menopausal Symptoms
First Posted Date
2003-01-27
Last Posted Date
2013-09-20
Lead Sponsor
Regional Oncologic Center
Target Recruit Count
1300
Registration Number
NCT00003771
Locations
🇳🇴

Norwegian Radium Hospital, Oslo, Norway

🇫🇮

Helsinki University Central Hospital, Helsinki, Finland

🇨🇭

Breast Center, Zurich, Switzerland

and more 3 locations

Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus

Not Applicable
Completed
Conditions
Systemic Lupus Erythematosus
First Posted Date
2000-08-04
Last Posted Date
2005-06-24
Lead Sponsor
National Center for Research Resources (NCRR)
Target Recruit Count
970
Registration Number
NCT00006133
Locations
🇺🇸

Louisiana State University School of Medicine, Shreveport, Louisiana, United States

🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

🇺🇸

Pritzker School of Medicine, Chicago, Illinois, United States

and more 14 locations
© Copyright 2025. All Rights Reserved by MedPath